Vanguard Global Advisers’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
Other funds holding CSTL
Vanguard Global Advisers's CSTL Position: Q3 2026 in Review
Vanguard Global Advisers increased its Castle Biosciences (CSTL) stake by 1.3% in Q3 2026, buying an estimated $4.35K and bringing the position to 11,646 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #2177.
Vanguard Global Advisers first reported a position in CSTL in Q1 2026 and has held it in 3 quarters since. 201 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.
- Vanguard Global Advisers held 11,646 shares of Castle Biosciences worth $414K as of Q3 2026.
- Vanguard Global Advisers bought 144 Castle Biosciences shares in Q3 2026, an estimated $4.35K.
- Castle Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2177 holding.
- Vanguard Global Advisers first reported a position in Castle Biosciences in Q1 2026 and has held it in 3 quarters since.
- 201 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.